Zosano Pharma Corp ZSANQ
We take great care to ensure that the data presented and summarized in this overview for Zosano Pharma Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZSANQ
View allLatest Institutional Activity in ZSANQ
Top Purchases
Top Sells
About ZSANQ
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Insider Transactions at ZSANQ
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 06
2022
|
Steven Lo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
442
-3.25%
|
$0
$0.71 P/Share
|
|
Jun 06
2022
|
Christine Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
82
-1.92%
|
$0
$0.71 P/Share
|
|
Mar 31
2022
|
Steven Lo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,633
-4.88%
|
$0
$0.21 P/Share
|
|
Mar 31
2022
|
Donald J Kellerman VP, Clinical Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
4,006
-6.64%
|
$0
$0.21 P/Share
|
|
Mar 31
2022
|
Christine Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,116
-5.25%
|
$0
$0.21 P/Share
|
|
Nov 23
2021
|
Kenneth Greathouse Director |
SELL
Open market or private sale
|
Direct |
10,000
-18.69%
|
$0
$0.6 P/Share
|
|
Oct 15
2021
|
Steven Lo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,750
+19.69%
|
-
|
|
Oct 15
2021
|
Christine Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,250
+26.69%
|
-
|
|
Oct 15
2021
|
Donald J Kellerman VP, Clinical Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+14.22%
|
-
|
|
Jun 10
2021
|
Joseph P Hagan Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.0%
|
-
|
|
Jun 10
2021
|
Kleanthis G Xanthopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+38.86%
|
-
|
|
Jun 10
2021
|
Kenneth Greathouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+21.9%
|
-
|
|
Jun 10
2021
|
Steve Elms Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.0%
|
-
|
|
Jun 10
2021
|
Linda Grais Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.0%
|
-
|
|
Jun 04
2021
|
Christine Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,709
-1.71%
|
$0
$0.8 P/Share
|
|
Jun 04
2021
|
Donald J Kellerman VP, Clinical Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,709
-3.28%
|
$0
$0.8 P/Share
|
|
Jun 04
2021
|
Hayley Lewis Officer |
SELL
Open market or private sale
|
Direct |
1,709
-3.32%
|
$0
$0.8 P/Share
|
|
Jun 04
2021
|
Steven Lo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,158
-3.47%
|
$0
$0.8 P/Share
|
|
May 17
2021
|
Kenneth Greathouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+35.29%
|
$0
$0.73 P/Share
|
|
Mar 30
2021
|
Christine Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
81,250
+44.83%
|
-
|